Search For "glenmark pharmaceuticals"
Glenmark's post-marketing surveillance shows no safety concerns on use of
Updated : 4 years, 6 months ago IST
New Delhi [India], September 15 (ANI): The Glenmark Pharmaceuticals' post-marketing surveillance (PMS) study has shown no safety concerns with the use of Favipiravir (FabiFlu®[?]) in India for COVID-19 infection.
Read More
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY fo
Updated : 4 years, 7 months ago IST
Mumbai (Maharashtra) [India], August 14 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2021.
Read More
Fitch affirms Glenmark Pharmaceuticals at BB on IPO of API business
Updated : 4 years, 7 months ago IST
Singapore, August 10 (ANI): Fitch Ratings has affirmed Glenmark Pharmaceuticals Ltd's long-term issuer default rating at BB after its active pharmaceutical ingredient (API) business completed an initial public offering (IPO).
Read More
Glenmark, Canada's SaNOtize to commercialise nasal spray for Covid-19 trea
Updated : 4 years, 7 months ago IST
Mumbai (Maharashtra) [India], August 2 (ANI): Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research and Development Corp on Monday announced an exclusive long term strategic partnership to manufacture, market and distribute nitric oxide nasal spray (NONS) for Covid-19 treatmen
Read More
Glenmark to conduct phase III trials of nasal spray it claims to be effect
Updated : 4 years, 8 months ago IST
New Delhi [India], July 8 (ANI): Glenmark Pharmaceuticals will be conducting a Phase III trial on a nasal spray, which it claims to be effective in the treatment of COVID-19.
Read More
Fitch affirms Glenmark Pharmaceuticals at BB with stable outlook
Updated : 4 years, 8 months ago IST
Singapore, July 6 (ANI): Fitch Ratings has affirmed Glenmark Pharmaceuticals Ltd's long-term issuer default rating at BB with a stable outlook.
Read More
Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib C
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 25 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic version of Ofev®1 Capsules, 100 mg and 1
Read More
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 23 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials, the generic version of BROVA
Read More
Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu®
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 9 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India.
Read More
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 4 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Theophylline Extended-release Tablets, 300 mg and 450 mg, bioequivalent and therapeutically equivalent
Read More
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 m
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 1 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel® Tablets, 200 mg and 400 mg of Eisai, Inc.
Read More
Glenmark's consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21
Updated : 4 years, 9 months ago IST
Mumbai (Maharashtra) [India], May 31 (ANI/PRNewswire): EBITDA growth of 22.7 per cent to Rs 20,844 Mn with margins of 19 per cent. Consolidated Net Profit of Rs 9,701 Mn with growth of 25 per cent in FY21.
Read More